Background/aim: Despite the fact that the COVID-19 pandemic has been going on for over 5 months, there is yet to be a standard management policy for all patients including those with mild-to-moderate cases. We evaluated the role of early hospitalization in combination with early antiviral therapy with COVID-19 patients in a tertiary care university hospital. Materials and methods: This was a prospective, observational, single-center study on probable/confirmed COVID-19 patients hospitalized in a tertiary care hospital on COVID-19 wards between March 20 and April 30, 2020. The demographic, laboratory, and clinical data were collected. Results: We included 174 consecutive probable/confirmed COVID-19 adult patients hospitalized in the Internal Medicine wards of the University Adult Hospital between March 20 and April 30, 2020. The median age was 45.5 (19-92) years and 91 patients (52.3%) were male. One hundred and twenty (69%) were confirmed microbiologically, 41 (23.5%) were radiologically diagnosed, and 13 (7.5%) were clinically suspected (negative microbiological and radiological findings compatible with COVID-19); 35 (20.1%) had mild, 107 (61.5%) moderate disease, and 32 (18.4%) had severe pneumonia. Out of 171 cases, 130 (74.3%) showed pneumonia; 80 were typical, and 50 showed indeterminate infiltration for COVID-19. Patients were admitted within a median of 3 days (0-14 days) after symptoms appear. The median duration of hospitalization was 4 days (0-28 days). In this case series, 13.2% patients were treated with hydroxychloroquine alone, 64.9% with hydroxychloroquine plus azithromycin, and 18.4% with regimens including favipiravir. A total of 15 patients (8.5%) were transferred to the ICU. Four patients died (2.2%). Conclusion: In our series, 174 patients were admitted to the hospital wards for COVID-19, 69% were confirmed with PCR and/or antibody test. At the time of admission, nearly one fifth of the patients had severe diseases. Of the patients, 95.4% received hydroxychloroquine alone or in combination. The overall case fatality rate was 2.2%.
COVID-19, noncritical illness, hydroxychloroquine, favipiravir
BAŞARAN, NURSEL ÇALIK; UYAROĞLU, OĞUZ ABDULLAH; DİZMAN, GÜLÇİN TELLİ; ÖZIŞIK, LALE; ŞAHİN, TAHA KORAY; TAŞ, ZAHİT; İNKAYA, AHMET ÇAĞKAN; KARAHAN, SEVİLAY; ALP, ŞEHNAZ ÖZYAVUZ; ALP, ALPASLAN; METAN, GÖKHAN; ZARAKOL, IŞKIN PINAR; GÜVEN, GÜLAY SAİN; ÖZ, ŞERİFE GÜL; and İSKİT, ARZU TOPELİ
"Outcome of noncritical COVID-19 patients with early hospitalization and early antiviraltreatment outside the ICU,"
Turkish Journal of Medical Sciences: Vol. 51:
2, Article 4.
Available at: https://journals.tubitak.gov.tr/medical/vol51/iss2/4